background
rna
virus
rapidli
accumul
genet
variat
give
rise
synthet
lethal
sl
deleteri
sd
mutat
synthet
lethal
mutat
nonleth
alon
lethal
combin
one
genom
studi
develop
cancer
therapi
principl
also
use
fastevolv
rnavirus
inde
target
protein
site
involv
sd
sl
interact
drug
would
render
mutat
site
lethal
result
set
strategi
detect
intragen
pair
sl
sd
surfac
protein
predict
less
escap
drug
target
site
detect
sd
sl
studi
hiv
proteas
pr
revers
transcriptas
rt
sequenc
align
two
group
vih
individu
treat
drug
nt
use
seri
statist
approach
abl
propos
bona
fide
sd
sl
coupl
focus
spatial
close
covari
sd
sl
coupl
surfac
protein
found
sd
sl
group
proteas
revers
transcriptas
could
good
candid
form
pocket
accommod
potenti
drug
conclus
thu
design
drug
target
specif
sd
sl
group
would
allow
viru
mutat
residu
involv
group
without
lose
essenti
function
moreov
also
show
select
pressur
induc
treatment
lead
appear
new
mutat
chang
mutat
landscap
protein
drive
exist
differenti
sd
sl
coupl
drugtreat
nontreat
group
thu
new
antivir
drug
design
differ
target
group
review
articl
review
neil
greenspan
csaba
pal
simon
classic
sl
genet
interact
involv
nonleth
mutat
carri
two
gene
whose
combin
lead
cell
death
extens
use
studi
geneproduct
interact
secret
pathway
yeast
bacteria
use
develop
anticanc
therapi
pinpoint
gene
say
x
whose
inactiv
form
pair
sl
mutat
cancercaus
gene
context
drug
target
gene
x
gene
respons
diseas
synthet
lethal
relationship
appear
product
gene
x
render
nonfunct
action
drug
thu
exist
nonfunct
protein
provok
lethal
phenotyp
lead
cancer
cell
death
effect
drug
normal
cell
would
chang
phenotyp
thu
induc
secondari
effect
base
paradigm
describ
slightli
differ
concept
uncov
new
druggabl
target
rna
virus
use
intragen
slbase
strategi
inde
rnavirus
escap
drug
vaccin
due
mutat
target
therapeut
molecul
develop
circumv
problem
pocketbind
drug
target
viral
fundament
function
pinpoint
viru
mutat
without
lose
relev
essenti
function
figur
four
invari
residu
fulfil
condit
rare
protein
rnavirus
notion
invari
extend
group
residu
intragen
sl
synthet
deleteri
sd
exploit
purpos
simplic
call
sdl
ensembl
sd
sl
group
amino
acid
spatial
close
say
less
two
residu
locat
protein
surfac
provid
suitabl
therapeut
target
residu
either
invari
member
sl
group
due
two
featur
essenti
protein
function
invari
target
uniqu
might
minim
even
prevent
viral
escap
treatment
variou
studi
perform
describ
pairwis
higherord
site
correl
within
rnaviru
protein
employ
variou
approach
inform
theori
non
synonym
versu
synonym
mutat
bayesian
network
etc
use
gener
kernel
ridg
regress
maximum
entropi
model
other
describ
gener
interest
concept
fit
landscap
unfortun
goal
make
differ
compensatori
mutat
cm
sl
pair
moreov
interest
point
potenti
druggabl
site
one
main
aim
work
specif
develop
viral
rna
sl
simul
rather
detect
preliminari
work
take
hiv
proteas
model
describ
posit
involv
sdl
coupl
method
use
yield
result
compar
obtain
team
work
subject
howev
sole
knowledg
amino
acid
aa
posit
part
molecular
pictur
know
exact
natur
aa
involv
sdl
coupl
import
moreov
sdl
coupl
expect
exist
alon
rather
within
context
mutat
network
involv
coupl
sdl
cm
final
uncov
function
covari
must
exclud
background
linkag
disequilibrium
bld
sum
sequenc
align
threedimension
structur
develop
strategi
involv
statist
test
phylogeni
structur
bind
site
construct
silico
tool
predict
potenti
therapeut
target
tool
test
two
hiv
protein
proteas
pr
revers
transcriptas
rt
allow
us
describ
five
target
consist
sl
invari
posit
greatli
minim
emerg
drug
resist
step
predict
drug
target
silico
defin
protein
region
potenti
druggabl
target
avoid
therapeut
escap
focus
sdl
coupl
figur
four
invari
posit
locat
vicin
seven
step
necessari
need
first
identifi
pair
interdepend
site
defin
examin
variant
posit
accumul
mutat
specif
variant
posit
test
pair
use
statist
test
describ
materi
method
mm
section
commonli
use
defin
depend
posit
coupl
respond
posit
test
taken
interdepend
pair
coupl
residu
may
coantivari
two
main
reason
either
interdepend
coupl
cm
sdl
deriv
bld
sdl
qualifi
druggabl
target
allow
therapeut
escap
sdl
coupl
defin
number
observ
pair
mutat
residu
smaller
number
expect
pair
thu
defin
dissimilar
coeffici
neg
sdl
coupl
posit
cm
coupl
see
materi
method
filter
result
explor
keep
pair
locat
protein
surfac
access
locat
known
therapeut
target
access
threshold
greater
use
asa
softwar
implement
allan
et
al
base
pr
structur
pdb
rt
structur
pdb
next
prove
sdl
coupl
deriv
common
ancestor
ie
exclud
bld
posit
coupl
underw
test
codon
underli
two
posit
comput
number
synonym
non
synonym
mutat
number
nonsynonym
mutat
pair
aa
twice
much
number
synonym
mutat
pair
ss
consid
pair
codon
undergo
posit
select
pressur
pair
therefor
assum
deriv
common
ancestor
word
deriv
bdl
figur
pr
brown
rt
keep
mind
idea
suggest
druggabl
target
retain
sdl
coupl
close
space
less
structur
final
invari
posit
mutat
relev
posit
rel
ancestr
sequenc
although
infrequ
also
taken
account
design
inescap
drug
target
thu
invari
posit
less
sdl
posit
also
kept
last
step
determin
drugabl
group
residu
first
approach
use
qsitefind
softwar
list
import
bind
site
protein
structur
figur
pr
figur
brown
area
rt
repres
bld
weaker
bigger
chanc
pair
interdepend
residu
come
common
ancestor
pair
success
statist
test
deriv
common
ancestor
repres
heatmap
pr
figur
venn
diagram
rt
figur
compar
result
rhee
et
al
interdepend
pair
use
detect
gamet
disequilibrium
result
given
coeffici
valu
correl
coeffici
r
result
given
r
correl
coeffici
valu
describ
patient
antirt
treatment
close
space
surfac
rt
five
coupl
posit
interdepend
test
two
reject
bld
test
inde
test
perform
rhee
et
al
concern
pr
interdepend
coupl
describ
rhee
et
al
one
close
space
pr
surfac
found
posit
one
algorithm
previou
result
three
group
also
confirm
new
strategi
except
come
bld
final
distinguish
sdl
cm
determin
dissimilar
coeffici
pair
residu
coupl
addit
file
tabl
repres
result
pr
addit
file
tabl
rt
intermedi
result
valid
statist
test
sdl
determin
display
tabl
result
show
half
interdepend
coupl
come
common
ancestor
half
involv
sdl
coupl
identifi
group
posit
becom
futur
target
invari
posit
locat
within
sdl
coupl
determin
number
sdl
time
higher
rtt
group
three
group
result
come
fact
rt
time
longer
pr
sequenc
treat
group
contain
mutat
next
sdl
coupl
invari
posit
vicin
gather
form
graph
subgraph
posit
graph
tabl
repres
potenti
futur
target
prnt
prt
graph
figur
contain
two
subgraph
rtnt
figur
graph
three
rtt
figur
graph
seven
note
subgraph
contain
two
posit
exclud
form
realist
bind
site
target
realli
druggabl
group
posit
compos
subgraph
predict
good
target
avoid
resist
howev
therapeut
interest
target
also
good
bind
site
ie
pocketshap
compos
atom
small
molecul
bind
first
approxim
test
possibl
use
qsitefind
program
threedimension
pr
structur
chosen
protein
data
bank
qsitefind
determin
protein
region
could
form
bind
pocket
kept
posit
intersect
subgraph
result
qsitefind
bind
pocket
tabl
list
aa
group
fulfil
condit
describ
begin
section
group
therefor
candid
therapeut
target
form
predict
good
bind
site
low
potenti
gener
drugresist
highlight
two
group
pr
structur
figur
first
one
contain
posit
blue
figur
number
tabl
site
volum
common
patient
treat
untreat
patient
second
one
contain
posit
red
figur
number
tabl
site
volum
use
untreat
patient
interestingli
studi
bonhoeff
group
fit
landscap
describ
region
defin
character
strong
epistasi
region
previous
describ
import
protein
function
two
bestscor
target
defin
qsitefind
softwar
correspond
activ
site
pr
major
drug
say
protein
bind
activ
site
unfortun
resist
molecul
appear
besid
find
sdl
area
highlight
three
group
rt
structur
figur
first
one
contain
posit
blue
figur
number
tabl
site
volum
common
treat
untreat
patient
note
posit
disappear
treat
group
target
local
rt
finger
second
one
local
thumb
contain
posit
red
figur
number
tabl
site
volum
appear
untreat
set
last
one
involv
posit
yellow
figur
number
tabl
site
volum
local
rt
palm
relev
treat
set
interestingli
second
third
target
involv
dna
bind
process
thu
far
result
tell
us
anyth
natur
aa
involv
coupl
inde
given
posit
involv
cm
sdl
relationship
concern
two
differ
aa
posit
relationship
interdepend
reason
also
compil
list
specif
aa
involv
sdl
cm
coupl
influenc
gener
mutat
landscap
protein
aa
coupl
locat
posit
dissimilar
coeffici
list
addit
file
tabl
pr
addit
file
tabl
rt
tabl
appear
clearli
sdl
cm
coupl
necessarili
treat
untreat
patient
set
coupl
covari
one
set
one
e
g
pr
regard
rt
number
sl
coupl
untreat
set
much
smaller
number
coupl
treat
set
tabl
mean
mani
coupl
common
group
obvious
potenti
druggabl
target
group
patient
figur
thu
keep
mind
potenti
drug
abl
block
rt
pr
patient
treat
patient
interpret
fact
target
describ
lie
outsid
activ
site
residu
constitut
protein
activ
site
gener
respons
chemic
reaction
allow
enzymat
activ
protein
howev
activ
site
essenti
part
protein
function
carri
threedimension
structur
proteas
studi
show
flexibl
structur
allow
flap
open
order
accommod
substrat
obviou
open
flap
essenti
function
enzymat
activ
therefor
quit
possibl
block
essenti
function
without
dock
drug
directli
activ
site
best
exampl
exist
nonnucleosid
revers
transcriptas
inhibitor
would
like
develop
softwar
abl
gener
tabl
interdepend
residu
sort
best
aa
group
uncov
inescap
drug
target
strategi
appli
protein
especi
rna
virus
flu
coronaviru
hepat
c
viru
provid
enough
mutat
sequenc
avail
databas
best
interdepend
aa
group
could
test
assess
whether
arrang
form
druggabl
pocket
protein
surfac
qsitefind
allow
first
approxim
pocket
detect
enrich
studi
consid
flexibl
natur
protein
discov
suitabl
pocket
techniqu
allow
descript
potenti
target
must
biolog
valid
prove
carri
essenti
function
viral
fit
one
major
aspect
therapeut
escap
along
variat
interdepend
drug
increas
select
pressur
alter
gener
mutat
landscap
target
viral
protein
inde
sever
posit
mutat
treat
set
generatemaintain
viral
drug
resist
new
mutat
drastic
impact
fit
viru
sever
posit
could
also
mutat
maintainincreas
fit
newli
mutat
virus
could
interest
creat
sequenc
databas
sequenc
would
associ
viral
fit
measur
averag
copi
number
blood
inform
hand
base
quasispeci
theori
principl
would
easi
test
exist
sdl
group
sequenc
correl
low
fit
ie
low
copi
number
thu
could
show
escap
drug
viru
make
mutat
within
sdl
group
pay
price
decreas
replic
potenti
choic
sdl
invari
posit
uniqu
compon
effect
druggabl
target
ultim
aim
reduc
even
elimin
drugresist
result
describ
two
new
potenti
target
pr
rt
offer
unusu
strategi
sinc
target
necessarili
treat
untreat
patient
druginduc
select
pressur
reveal
new
mutat
often
reduc
fit
mutat
organ
variant
possess
mutat
enabl
acquir
better
fit
select
two
success
wave
mutat
chang
gener
equilibrium
cm
sdl
two
patient
set
lead
differ
drug
develop
strategi
near
futur
import
administ
differ
molecul
naiv
never
treat
patient
treat
patient
sometim
singl
mutat
allow
virus
escap
treatment
mutat
appear
sl
posit
function
lost
descript
target
includ
invari
posit
mutat
prevent
protein
function
howev
first
mutat
appear
alon
reach
limit
strategi
resist
develop
target
unus
equival
target
describ
past
howev
drug
dock
target
consist
invari
residu
sl
pair
best
way
block
viral
resist
wet
biolog
describ
exist
situat
residu
appear
mutat
concomitantli
induc
resist
pi
convers
wet
biolog
assess
situat
two
residu
requir
mutat
togeth
induc
resist
entail
loss
essenti
function
inde
situat
never
appear
focus
kind
coupl
constitut
sdl
cm
describ
new
potenti
protein
pocket
could
bound
potenti
drug
abl
hiv
viru
could
escap
treatment
without
loos
essenti
function
addit
file
tabl
summar
interdepend
relationship
ie
lookup
tabl
describ
exact
aa
form
cm
sdl
method
describ
manuscript
appli
hiv
use
sequenc
dataset
fact
limit
total
number
mutat
per
posit
inde
order
studi
abil
two
posit
mutat
simultan
necessari
prove
posit
variabl
rna
virus
mutat
approxim
time
faster
organ
abil
allow
speci
prime
candid
method
howev
sinc
number
sequenc
genom
constantli
increas
almost
certain
near
futur
method
also
use
find
new
drug
bacteria
antibiot
resist
becom
major
problem
public
health
drug
develop
base
abil
bind
activ
site
therefor
bind
activ
site
similar
protein
thu
gener
possibl
side
effect
techniqu
allow
target
region
outsid
activ
site
might
help
defin
drug
fewer
side
effect
alreadi
said
necessari
experiment
valid
bioinformat
predict
import
prove
target
essenti
protein
function
question
could
address
studi
mutat
residu
compos
target
affect
viral
activ
small
molecul
bind
target
select
posit
found
use
virtual
high
throughput
screen
larg
chemic
librari
potenti
lead
emerg
hit
may
refin
structureact
studi
final
inhibit
viral
activ
presenc
molecul
valid
qualiti
inhibitor
pr
sequenc
rt
sequenc
subtyp
b
nontreat
patient
download
th
may
stanford
univers
hiv
drug
resist
databas
http
hivdbstanfordedu
sequenc
patient
treat
pi
download
well
rt
sequenc
patient
nrti
andor
nnrti
sequenc
two
protein
set
full
length
ie
contain
posit
pr
posit
rt
order
defin
access
aa
extern
ligand
ie
potenti
drug
comput
surfac
access
solvent
use
asa
softwar
avail
rpb
base
pr
structur
pdb
rt
structur
pdb
aa
access
threshold
greater
consid
access
previou
protein
align
recod
focu
mutat
aa
statu
rel
refer
sequenc
aa
compar
aa
ancestr
sequenc
posit
recod
equival
ancestr
sequenc
otherwis
n
defin
posit
lie
surfac
protein
variant
ie
mutat
posit
taken
account
coupl
defin
interdepend
follow
statist
test
fisher
exact
test
covari
code
r
use
examin
variant
posit
pair
pr
rt
overcom
bia
caus
larg
number
test
perform
pvalu
readjust
use
fdr
method
r
adjust
pvalu
retain
pair
correspond
pvalu
black
heatmap
figur
number
black
area
figur
rt
test
measur
linkag
disequilibrium
nonrandom
associ
calcul
two
allel
two
loci
test
comput
pair
posit
variant
access
use
input
recod
align
accord
wang
data
pair
correspond
pvalu
non
red
heatmap
figur
number
red
area
figur
rt
r
index
deriv
correl
index
lewontin
use
recod
align
test
r
comput
perl
accord
pair
posit
variant
access
pair
correspond
pvalu
black
heatmap
figur
number
green
area
figur
rt
last
test
ij
take
account
true
natur
aa
fact
mutat
thu
calcul
protein
align
recod
method
accord
noirvirt
condit
coupl
expect
time
kept
given
pvalu
sens
calcul
coupl
posit
detect
use
random
shuffl
method
due
multipl
e
fdr
three
set
pair
correspond
pvalu
black
heatmap
figur
number
blue
area
figur
rt
use
dna
sequenc
coupl
non
synonym
aa
coupl
synonym
mutat
ss
determin
coeffici
comput
data
explain
coupl
determin
interdepend
one
comput
sign
dissimilar
coeffici
neg
number
expect
aa
coupl
superior
number
observ
coupl
sdl
pair
otherwis
compensatori
pair
cm
furthermor
coeffici
convent
sign
follow
nob
b
j
nex
b
j
b
j
specif
aa
posit
b
specif
aa
posit
j
b
j
comput
review
report
base
amino
acid
sequenc
align
either
treat
nontreat
individu
identifi
amino
acid
appear
access
lethal
deleteri
simultan
mutat
synthet
lethal
sl
synthet
deleteri
sd
residu
author
also
identifi
appar
invari
pr
rt
amino
acid
therefor
assum
critic
molecular
function
central
hypothesi
pursu
drug
abl
bind
slsd
pair
suffici
proxim
one
anoth
plu
one
amino
acid
identifi
invari
molecular
surfac
would
serv
rel
nonmut
target
site
inhibitori
drug
success
object
would
obviou
valu
effort
minim
spread
hiv
manag
infect
individu
alreadi
carri
hiv
present
manuscript
author
also
demonstr
exposur
treatment
modifi
pr
rt
mutat
landscap
given
content
present
manuscript
employ
method
alreadi
describ
previou
articl
brouillet
et
review
comment
first
articl
enabl
us
significantli
chang
method
use
inde
previou
method
solv
three
import
point
discrimin
pair
residu
function
interdepend
due
common
ancestor
answer
review
previou
articl
use
lewontin
deriv
test
new
test
use
compar
rate
synonym
non
synonym
mutat
pair
posit
statist
studi
base
singl
test
three
test
implement
r
fisher
natur
amino
acid
taken
account
boolean
result
mutat
nonmut
calcul
new
statist
test
allow
defin
exact
natur
aa
form
interdepend
coupl
applic
find
concern
rt
new
result
sinc
first
paper
concern
pr
serv
control
new
studi
two
tabl
rt
pr
describ
major
pair
mutat
natur
associ
amino
acid
sequenc
set
addit
file
tabl
addit
file
tabl
tabl
essenti
drug
design
chemist
chemoinformatician
regard
biolog
valid
result
beyond
scope
present
paper
current
set
partnership
hiv
virolog
laboratori
defin
adequ
experiment
protocol
appli
review
comment
confid
invari
residu
fact
critic
function
exampl
put
invari
tryptophan
residu
start
second
framework
region
within
immunoglobulin
heavi
light
chain
variabl
domain
sequenc
prior
studi
j
sharon
j
immunol
apr
found
critic
function
antibodi
known
antigen
specif
sharon
mutat
trp
ala
sitedirect
mutagenesi
without
appar
effect
antibodi
reactiv
antigen
review
csaba
pal
biolog
research
center
hungari
main
object
paper
identifi
intragen
pair
residu
show
synthet
lethal
interact
hiv
protein
author
use
inform
uncov
drug
target
site
could
potenti
mitig
evolut
resist
manuscript
well
written
present
idea
goe
straight
point
strategi
follow
author
knowledg
innov
valid
approach
tri
overcom
drug
resist
hiv
therapi
fact
approach
due
target
specif
effici
would
also
benefici
develop
therapeut
approach
less
toxic
side
effect
therapi
newborn
infant
young
children
togeth
multidrug
resist
import
problem
solv
hiv
therapi
idea
creat
softwar
tool
identif
inescap
drug
target
import
could
help
medicin
chemist
focu
research
compound
bind
predict
target
site
author
discuss
benefit
futur
perspect
work
deepli
paper
exampl
possibl
appli
methodolog
target
protein
also
briefli
discuss
manuscript
author
also
discuss
vitro
vivo
valid
report
result
includ
possibl
limit
studi
reason
drug
fit
prnt
rtnt
case
use
prt
rtt
case
clear
usabl
way
around
